血生成标记物作为癌症相关静脉血栓栓塞的预测剂:系统性审查
Tua Gyldenholm1,2, Anne-Mette Hvas3, Thomas Decker Christensen2,4
1Department of Clinical Biochemistry, Thrombosis and Haemostasis Research Unit, Aarhus University Hospital, Aarhus, Denmark.
Seminars in thrombosis and hemostasis
|October 9, 2023
概括
血栓生成的标记物,包括前血栓片段1.2 (F1.2),预测癌症患者的静脉血栓栓塞 (VTE). F1.2显示了最强的关联和癌症相关的VTE风险评估得分的改善.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 血栓形成研究研究
背景情况:
- 静脉血栓栓塞 (VTE) 是癌症患者疾病和死亡的重要原因.
- 确定可靠的生物标志物来预测与癌症相关的VTE对于患者管理至关重要.
- 血栓生成的标记物是静脉瘤预测的潜在候选者.
研究的目的:
- 系统地审查三种血栓生成生物标记物的预测能力:前血栓片段1.2 (F1.2),血栓-抗血栓复合物 (TAT) 和ex vivo血栓生成.
- 为了评估这些生物标志物在成年患者的固体和血液恶性瘤.
- 评估这些标志物是否可以改善现有的VTE风险评估得分.
主要方法:
- 在PubMed和Embase数据库中识别的研究的系统审查.
- 遵守系统审查和元分析 (PRISMA) 准则的首选报告项目.
- 使用国家心脏,肺和血液研究所工具进行包含研究的质量评估;协议注册在PROSPERO.
主要成果:
- 包括24篇论文,报告了F1.2 (11项研究),TAT (9项研究) 和ex vivo血栓生成 (12项研究) 的数据.
- 尽管研究异质和质量可变,但F1.2,TAT和ex vivo血栓生成都与VTE的发展有关.
- 输血栓片段1.2 (F1.2) 显示出与静脉瘤最明显的关联,并提高了已确定的风险得分的精度.
结论:
- 在患有VTE的癌症患者中,血生成标志物升高.
- 前列腺血片段1.2 (F1.2) 成为预测癌症患者VTE的特别有前途的生物标志物.
- 这些发现支持了血栓生成标志物的临床实用性,用于控制瘤学中的VTE风险.
相关概念视频
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
13
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
13
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:30Venous Thrombosis I: Introduction
12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
729
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
729
01:30Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K